News

A new retrospective study claimed a rarity of cytogenetic and molecular monitoring exists among patients with chronic myelogenous leukemia (CML) treated in a community setting; however, one researcher is challenging that claim.

A comparison preclinical study pitting a sugary diet with one less sweet shows the former resulting in increased breast cancer tumor growth and metastasis.

Venetoclax has been granted priority review status by the FDA for use in adults with chronic lymphocytic leukemia (CLL) following at least 1 prior therapy. This patient population includes those with a 17p deletion (del[17p]), according to codevelopers of the BCL-2 inhibitor AbbVie and Genentech.

A new 26-gene-screening panel, dubbed myBRCA HiRisk, hitting the market in the first quarter of 2016 aims to advance the prevention of hereditary breast and ovarian cancer.

Despite the initial controversy caused over 6 years ago, the US Preventive Services Task Force (USPSTF) has released a final version of its guidelines that stick to its initial assessment.

Although FGFR pathway deregulation has been identified frequently in NSCLC, clinical activity of FGFR inhibitors has been considered disappointing and modest, at best, to date.

A current estimation shows that roughly 25% of metastatic castration-resistant prostate cancers (mCRPC) contain alterations in DNA repair genes. These would normally code for proteins to correct errors arising when cells duplicate their DNA before cell division.

Omid Hamid, MD, discusses the upcoming Annual International Symposium on Melanoma and Other Cutaneous Malignancies.

A gene associated with the suppression of tumor growth has been found to act in the opposite manner in some forms of colorectal cancer (CRC), according to researchers at the University of Missouri School of Medicine.

With an expanding treatment paradigm for patients with colorectal cancer (CRC) at their fingertips, oncologists are working out the best methods of use for their new armamentarium, says John L. Marshall, MD.

The use of computed-tomography (CT)-planned high-dose-rate (HDR) intracavitary brachytherapy (BT) demonstrated excellent local control (LC) and survival for patients with stage I/II cervical carcinoma.

The programmed cell death 1 (PD-1) and PD-1 ligand (PD-L1) inhibitors "are going to disrupt the current treatment paradigm and will likely be the backbone of combination therapy," said Hans J. Hammers, MD, PhD.

An upcoming phase I trial seeks to evaluate a combination of interferon gamma-1b (ACTIMMUNE) and nivolumab (Opdivo) in patients with advanced solid tumors who have progressed on at least one prior systemic therapy.

The FDA has approved a new treatment consisting of a non-alcohol formulation of docetaxel in patients with breast cancer, non-small cell lung cancer, prostate cancer, gastric adenocarcinoma, and head and neck cancer.

An orphan drug designation has been granted to the multi-epitope folate receptor alpha (FRα) vaccine TPIV 200 as a treatment for patients with ovarian cancer by the FDA.

The FDA has received a new drug application for cabozantinib (Cometriq) as a treatment for patients with advanced renal cell carcinoma (RCC) who have received one prior therapy.

A new study has analyzed intratumoral heterogeneity (ITH) in 12 cancer types and found a "tolerable" level of genomic instability, independent of cancer type, beyond which a cancer may become less aggressive.

A correlation was drawn between adjuvant hormone therapy (AHT) and a 37% reduction in the risk of death in women with epithelial ovarian cancer, according to results of a 24-year study.

A new method of screening utilizing CA-125 and a risk assessment algorithm could drop risk of mortality from ovarian cancer in certain women, according to findings from the UK Collaborative Trial of Ovarian Cancer Screening.

Afatinib utilized as a frontline treatment reduced risk of progression or death by 27%, as compared to gefitinib in patients with EGFR-mutant non-small cell lung cancer. according to a recent phase IIb trial.

The FDA has assigned a breakthrough therapy status to the third-generation EGFR TKI BI-1482694 as a possible treatment for patients with T790M-positive non

While results from ongoing trials with atezolizumab, pembrolizumab, nivolumab, and avelumab in bladder cancer are eagerly awaited, there is one subset of patients who require special attention - patients with upper tract urothelial cancer (UTUC).

Talimogene laherparepvec (T-VEC; Imlygic) has been approved by the European Comission as a treatment for adult patients with unresectable stage IIIb, IIIc, and IVM1a melanoma that has not spread to the bone, brain, lung, or other viscera, based on the phase III OPTiM study.

A data metaanalysis supports the potential correlation between NAT2 slow acetylation and the risk of bladder cancer.

A high number of clinically relevant genomic alterations (CRGAs) were found in patients with advanced urothelial carcinoma (UC) using a comprehensive genomic profile (CGP).

Expanded approval for single-agent pembrolizumab (Keytruda) has arrived from the FDA to include frontline treatment for advanced melanoma regardless of BRAF status, based on a substantial improvement in progression-free and overall survival compared with ipilimumab (Yervoy) in the phase III KEYNOTE-006 trial

Urologists face a challenge in delineating the optimal sequence of treatment more and more as the goal for treating prostate cancer moves toward greater use of targeted therapies. While these treatment eradicate disease, urologists must minimize the risk of adverse events.

With a renewed armory of treatments consisting heavily of immunotherapies, urologists can employ new paradigms of treatment for patients with metastatic castration-resistant prostate cancer (mCRPC).

Patients with newly-diagnosed glioblastoma who received treatment with tumor- treating electrical fields in addition to temozolomide had nearly double the two-year survival of those who received temozolomide alone, according to an article published in the Journal of the American Medical Association.

Researchers discovered that pregnancy while in remission of Hodgkin lymphoma does not increase the risk of cancer relapse, making this report the first largest study to specifically examine the impacts of pregnancy as a potential trigger for relapse in Hodgkin lymphoma survivors.